Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Alliance for Clinical Trials in Oncology
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06931340CT.gov Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | — | Recruiting | — | — | — |
NCT07086651CT.gov A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC) | — | Completed | — | — | — |
NCT06378866CT.gov Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial | — | Recruiting | — | — | — |
NCT04947254CT.gov Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT04530552CT.gov Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | — | Active Not Recruiting | — | — | — |
NCT03902951CT.gov Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04585932CT.gov Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | — | Withdrawn | — | — | — |
NCT04423211CT.gov Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | — | Recruiting | — | — | — |
NCT04267887CT.gov Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03899077CT.gov Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP | — | Unknown | — | — | — |
Show 2 more trialsShow fewer
NCT03371719CT.gov Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial | — | Active Not Recruiting | — | — | — |
NCT03124433CT.gov Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apalutamide (this asset) | Alliance for Clinical Trials in Oncology | P3 | BB · 64 |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Degarelix | Baptist Health South Florida | P3 | BBB |
| Prednisone | Mayo Clinic | P4 | BBB |
| Enzalutamide | Pfizer | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BBB |
| Docetaxel | Alliance for Clinical Trials in Oncology | P3 | BB |
| Goserelin | Mayo Clinic | P3 | BB |
| Fludeoxyglucose | Jonsson Comprehensive Cancer Center | P2/3 | BB |
+41 more in the Prostate Carcinoma cohort
Other indications for Apalutamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BB · 67 |
| Metastatic Prostate Carcinoma | — | P4 | BB · 67 |
| Castration-Resistant Prostate Carcinoma | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apalutamide in Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apalutamide-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →